NXTCNextCure
About NextCure
NextCure (NASDAQ:NXTC) is a biotechnology company focused on discovering and developing novel immunotherapies for cancer and other immune-related diseases. By leveraging its proprietary FIND-IO™ platform, NextCure aims to identify and advance therapeutic proteins and peptides that harness the body's immune system to fight disease effectively. The company's pipeline of projects includes several promising candidates in different stages of development, aimed at addressing unmet medical needs across various oncological indications. With a commitment to innovation and patient welfare, NextCure's objective is to push the boundaries of scientific research to provide new, effective treatments that improve patient outcomes and quality of life.
What is NXTC known for?
Snapshot
Public US
Ownership
2015
Year founded
82
Employees
Maryland, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of NextCure
- NC318, an immunomedicine targeting Siglec-15, aimed at enhancing immune system's ability to fight cancer.
- NC410, a novel immune modulator designed to restore immune recognition and kill cancer cells.
- NC762, a monoclonal antibody that targets B7-H4, potentially inhibiting tumor growth.
- Collaboration with Yale University to identify novel cancer targets, leveraging NextCure's FIND-IO platform.
NextCure executive team
- Mr. Michael S. Richman MSBACo-Founder, CEO, President & Director
- Dr. Timothy Mayer Ph.D.Chief Operating Officer
- Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Mr. Steven P. Cobourn CPAChief Financial Officer
- Mr. Kevin G. ShawSenior VP & General Counsel
- Mr. Sourav Kundu Ph.D.Senior Vice President of Development & Manufacturing
- Dr. Sebastien Maloveste Ph.D.Senior Vice President of Business Development
- Dr. Udayan Guha M.D., Ph.D.Chief Medical Officer